A double-blind, randomized, placebo-controlled four-compartment parallel group, multicenter trial in outpatients with Generalized Anxiety Disorder (GAD): a 14-to 30-day drug-free interval preceded study entry. For all qualified patients, a 1-week, single-blind placebo washout period was followed by a 5-week, double-blind treatment phase involving a once daily oral dose of either 10 mg, 20 mg, or 40 mg of Serazapine (CGS15040), or placebo. The 40-mg group tended to perform better (larger decreases from baseline in the total Ham-A score) than the other groups.